Merrell Dow Pharmaceuticals

Sibia Neurosciences, Inc.

Sgx Pharmaceuticals, Inc.

Other

Merck + Co., Inc.

Merrell Pharmaceuticals, Inc.

Merrell Toraude Et Compagnie

Drexel University

Pharmaxis Ltd.

Ian A McDonald

Michael G Palfreyman

Philippe Bey

Mark E Wilson

Ruo W Steensma

Elisabeth Albrecht

William D Arnold

Andreas Gosberg

Benito Munoz

Jeffrey Paul Whitten

Zhe Li

Bruce M Baron

Pierre Bounaud

Francesco Gerald Salituro

Jean-Michel Andre Vernier

Robert Schwarcz

Brian Walter Eastman

Mark W Dudley

Nicholas David Cosford

Chixu Chen

Ronald C Bernotas

Stephanie Hopkins

Stefan N Gradl

Jeffrey S Sprouse

Paul A Sprengeler

Wan Y Shih

Wei-Heng Shih

Nicholas D P Cosford

Niall S Doherty

Hui Li

Jean-Noel Collard

Pierre-Yves Bounaud

Yu-Chieh Lu

Yada Schneider

Andrew Kopek

Laurie E Lambert

Ryan O'Malley

Zhe Li Bounaud

Boyd Lynn Harrison

Alan J Bitonti

David M Stemerick

Nicholas David Peter Cosford

Paul S Wright

R William McCallum

Mandar Deodhar

Jonathan Stuart Foot

Edwin J Schweiger

Craig Ivan Turner

Esa T Jarvi

Robert Steven Siegel

Stephen D Hess

Blake Alan Rowe

Steven Lee Wagner

Rowena Villanueva Cube

Mark Andrew Varney

Laura H Lewis

Sahar Keshavarz

Leo Solomon Bleicher

The invention provides method for making high coercivity magnetic materials based on FeNi alloys having a L1phase structure, tetratenite, and provides a system for accelerating production of these materials. The FeNi alloy is made by preparing a melt comprising Fe, Ni, and optionally one or more elements selected from the group consisting of Ti, V, Al, B, C, Mo, Ir, and Nb; cooling the melt and applying extensional stress and a magnetic field. This is followed by heating and cooling to form the L10 structure.

Method of tetratenite production and system therefor

A novel quantum dot capable of near infrared emissions at wavelengths of 750-1100 is made by forming solid solutions of metal sulfide, metal selenide or metal sulfide selenide by incorporating a suitable amount of an additional metallic element or elements to provide an emission wavelength in the range of 750 nm to 1100 nm. The quantum dots may be enabled for bioconjugation and may be used in a method for tissue imaging and analyte detection.

Water soluble nanocrystalline quantum dots capable of near infrared emissions

The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: (I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases. 

Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor

The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

Fused ring heterocycle kinase modulators

The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.

Pyrrolo-pyridine kinase modulators

In accordance with the present invention, there are provided methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds. Diseases contemplated include cerebral ischemia, chronic neurodegeneration, psychiatric disorders, schizophrenia, mood disorders, emotion disorders, disorders of extrapyramidal motor function, obesity, disorders of respiration, motor control and function, attention deficit disorders, concentration disorders, pain disorders, neurodegenerative disorders, epilepsy, convulsive disorders, eating disorders, sleep disorders, sexual disorders, circadian disorders, drug withdrawal, drug addiction, compulsive disorders, anxiety, panic disorders, depressive disorders, skin disorders, retinal ischemia, retinal degeneration, glaucoma, disorders associated with organ transplantation, asthma, ischemia and astrocytomas. The invention further discloses methods of preventing disease conditions related to diseases of the pulmonary system, diseases of the nervous system, diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the endocrine system, diseases of the exocrine system, diseases of the skin, cancer and diseases of the ophthalmic system. The invention also discloses pharmaceutically acceptable salt forms of heterocyclic compounds.

Methods of modulating processes mediated by excitatory amino acid receptors

In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system. Invention compounds may also act as insecticides, and as fungicides. Pharmaceutical compositions containing invention compounds also have wide utility.

Thiazolyl(pyridyl)ethyne compounds

A method for remotely monitoring and managing the operation of fare charging passenger carrying vehicles forming elements of a transportation system. The method is carried out as each vehicle travels a route to pick up and deliver passengers having previously established passenger accounts. The method comprises the steps of maintaining a wireless two-way data link between each vehicle and a system control center having stored passenger account data and maintaining a two-way data link between the system control center and a system management center to allow the system management center to exchange data with the system control center and with each vehicle. A fare charge schedule defining fare charges based on designated criteria is transferred from the system management center to the system control center. The identity of each passenger boarding each vehicle is transmitted to the system control center where the passenger identity is matched with the related passenger account within the system control center. An appropriate fare charge is assessed against the passenger account. A passenger account status report is then transmitted to the vehicle indicating that the fare charge has been accepted or declined. Vehicle passenger boarding is controlled in response to receipt of the passenger status report.

Real time internet-based transit management and control system with wireless vehicular data link

Growing community of inventors

Loveland, OH, United States of America

Ian A McDonald